NCT03453489 2025-04-10
AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With MetastaticNeuroendocrine Neoplasm
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
Clinical Trials
6 trialsNCT04713202 2023-02-10
NET-PACS
Big Ten Cancer Research Consortium
Phase 2 Withdrawn
NCT03722511 2022-11-03
Evaluating an Amino Acid Based Medical Food w/ Diarrhea in Carcinoid Syndrome & Other NETs
University of Kentucky
Phase 2 Completed
NCT04776876 2021-09-29
Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid Syndrome
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT04039516 2020-08-04
CHARRT
King's College Hospital NHS Trust
Phase 2 Unknown
NCT01172717 2013-07-26
Study of Panitumumab in the Treatment of Carcinoid Syndrome
Boston Medical Center
Phase 2 Withdrawn